Derolf A R, Laane E, Björklund E, Saft L, Björkholm M, Porwit Anna
Division of Hematology, Department of Medicine, Karolinska University Hospital Solna and Karolinska Institutet, Stockholm, Sweden.
Scand J Immunol. 2014 Dec;80(6):424-31. doi: 10.1111/sji.12223.
Dendritic cells (DCs) develop in the bone marrow from haematopoietic progenitor cells. Two subsets, plasmacytoid DCs (pDCs) and myeloid DCs (mDCs), have been identified. Little is known regarding DC levels in bone marrow of patients with acute myeloid leukaemia (AML) before and after chemotherapy. We investigated relative pDC and mDC levels in bone marrow from 37 hospital controls and 60 patients with AML [at diagnosis, complete remission (CR) and follow-up] using four-colour flow cytometry. The pDC immunophenotype was characterized as lin-/HLA-DR+/CD123 + and mDC as lin-/HLA-DR+/CD11c+. In 69% of patients with AML, no DCs were detected at diagnosis. At CR, mDC levels were the same in patients with AML and hospital controls while pDC levels were slightly lower. There was no association between minimal residual disease or survival rates and DC levels. Patients with low mDC levels at CR were more likely to suffer from complicated infections, although the difference was not statistically significant. Altogether, there was a profound decrease in DC levels in patients with AML at diagnosis. DC levels increased at CR and were higher than in hospital controls after post-remission therapy, suggesting that DCs recover after repeated chemotherapy. There may be an association between mDC levels and infectious complications.
树突状细胞（DCs）由造血祖细胞在骨髓中发育而来。已鉴定出两个亚群，即浆细胞样DCs（pDCs）和髓样DCs（mDCs）。关于急性髓系白血病（AML）患者化疗前后骨髓中DC水平的情况知之甚少。我们使用四色流式细胞术研究了37名医院对照者和60名AML患者（诊断时、完全缓解期和随访期）骨髓中相对pDC和mDC水平。pDC免疫表型特征为lin-/HLA-DR+/CD123 +，mDC为lin-/HLA-DR+/CD11c+。69%的AML患者在诊断时未检测到DCs。在完全缓解期，AML患者的mDC水平与医院对照者相同，而pDC水平略低。微小残留病或生存率与DC水平之间无关联。完全缓解期mDC水平低的患者更易发生复杂感染，尽管差异无统计学意义。总体而言，AML患者诊断时DC水平显著降低。完全缓解期DC水平升高，缓解后治疗后高于医院对照者，表明DCs在反复化疗后恢复。mDC水平与感染性并发症之间可能存在关联。
